IRIDEX Corporation (IRIX)
IRIXNASDAQ-CMBiotechnology: Electromedical & Electrotherapeutic Apparatus
$0.7002
-0.0124 (-1.74%) today
At the close, Nov 10, 4:00 PM ET. After hours $0.7002 –
- Market cap
- $12.30m
- P/E
- –
- EPS, last 4 quarters
- $-0.2000
- Dividend yield
- –
- Day range
- $0.7000 to $0.7400
- 52-week range
- $0.6070 to $1.65
- Average volume
- 459.5k
- Previous close
- $0.7126
Analysts
1 covering1 buy, 0 hold, 0 sell
Targets a year out average $2.75, +292.7% from here
Earnings
next estimate $-0.0400Next report Nov 17, 2026
Sep 2025
–
Dec 2025
–
Mar 2026
–
Jun 2026
–
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Jan 2026 | Apr 2026 | Jul 2026 |
|---|---|---|---|---|
| Revenue | $12.48m | $14.72m | $11.80m | $12.57m |
| Gross profit | $4.01m | $5.48m | $4.74m | $4.30m |
| Operating income | -$1.41m | -$15.0k | -$324.0k | -$1.03m |
| Net income | -$1.57m | -$184.0k | -$524.0k | -$1.27m |
Last four quarters: revenue $51.57m, margin -6.9%, free cash flow -$2.00m
News
8 latest- Iridex Reports Sustained Glaucoma Benefits With MicroPulse Laser Therapy At Two Years RTTNews · Oct 12, 2026
- IRIDEX (IRIX) Q2 2026 Earnings Call TranscriptThe Motley Fool · Aug 25, 2026
- IRIDEX Q2 Loss Widens Y/Y as Retina Weakness Weighs, Stock Down 15%Zacks · Aug 25, 2026
- Iridex Posts Q2 Results, Glaucoma Segment Shows Strength RTTNews · Aug 19, 2026
- Iridex Expands EyeProGPO Offering With EndoProbe Handpieces RTTNews · Jul 20, 2026
- IRIX Stock Up 4% As Q1 Loss Narrows Y/Y on Glaucoma Product GrowthZacks · May 25, 2026
- Iridex (IRIX) Q1 2026 Earnings TranscriptThe Motley Fool · May 19, 2026
- The Zacks Analyst Blog Microsoft, AbbVie, BHP, CBL & Associates Properties and IRIDEX Zacks · Apr 20, 2026
The company
Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, which include capital equipment and consumable probes for the ophthalmology market. The Company's proprietary MicroPulse® technology delivers the therapeutic benefits of laser treatment while minimizing tissue damage, offering a safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex's current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries.
- Sector
- Health Care
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- iridex.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.